Latest News on NGNE

Financial News Based On Company

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

https://www.benzinga.com/pressreleases/25/11/g48682080/accipiter-biosciences-emerges-from-stealth-with-12-7-million-in-seed-financing-to-deliver-de-novo-

Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities

This website offers investor tools designed to empower your financial decisions.

Value-Trades uses subscriptions for ongoing access. This section is only for one-time manual payments (for example: small balance adjustments or custom amounts you agree with us by email).

Manual One-Time Payment

Use this form to send a single payment (e.g., $5, $10, $15, etc.) for any agreed amount such as partial subscription catch-up, small adjustments, or one-off services.

Select Payment Amount:

Regular subscriptions are charged automatically through your plan. This form is only for extra one-time payments when requested.

Disclaimer

The Value-Trades website is intended for informational purposes only. The content provided on this website, including but not limited to recommendations, analysis, and opinions, should not be considered financial advice. Before making any investment decisions, whether buying or selling, based on information obtained from this website, it is imperative that you conduct your own thorough due diligence. This includes consulting with a qualified financial advisor, reviewing financial statements, and understanding the risks involved in any investment. The owner of this website shall not be held responsible for any financial losses incurred as a result of using the information provided herein. Investing in financial markets involves risk, and past performance is not indicative of future results. You are solely responsible for your investment decisions.

Financial News Based On Company

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

https://www.benzinga.com/pressreleases/25/11/g48682080/accipiter-biosciences-emerges-from-stealth-with-12-7-million-in-seed-financing-to-deliver-de-novo-

Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities

Manual One-Time Payment

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up! View Daily Trades Join Discussion

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion